Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTWP7HQ)

DTT Name CYP3A4 messenger RNA (CYP3A4 mRNA)
Synonyms
Taurochenodeoxycholate 6-alpha-hydroxylase (mRNA); Quinine 3-monooxygenase (mRNA); P450-PCN1 (mRNA); Nifedipine oxidase (mRNA); NF-25 (mRNA); HLp (mRNA); Cytochrome P450-PCN1 (mRNA); Cytochrome P450 NF-25 (mRNA); Cytochrome P450 HLp (mRNA); Cytochrome P450 3A4 (mRNA); Cytochrome P450 3A3 (mRNA); CYPIIIA4 (mRNA); CYPIIIA3 (mRNA); CYP3A3 (mRNA); Albendazole sulfoxidase (mRNA); Albendazole monooxygenase (sulfoxide-forming) (mRNA); 1,8-cineole 2-exo-monooxygenase (mRNA)
Gene Name CYP3A4
DTT Type
Clinical trial target
 [1]
BioChemical Class
mRNA target
UniProt ID
CP3A4_HUMAN
TTD ID
T90391
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
EC Number
EC 1.14.14.-
Sequence
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA
Function
In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e. g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,8-cineole 2-exo-monooxygenase. The enzyme also hydroxylates etoposide. Catalyzes 4-beta-hydroxylation of cholesterol. May catalyze 25-hydroxylation of cholesterol in vitro. Catalyzes sulfoxidation of the anthelmintics albendazole and fenbendazole. Cytochromes P450 are a group of heme-thiolate monooxygenases.
KEGG Pathway
Steroid hormone biosynthesis (hsa00140 )
Linoleic acid metabolism (hsa00591 )
Retinol metabolism (hsa00830 )
Metabolism of xenobiotics by cytochrome P450 (hsa00980 )
Drug metabolism - cytochrome P450 (hsa00982 )
Drug metabolism - other enzymes (hsa00983 )
Metabolic pathways (hsa01100 )
Bile secretion (hsa04976 )
Chemical carcinogenesis (hsa05204 )
Reactome Pathway
Aflatoxin activation and detoxification (R-HSA-5423646 )
Xenobiotics (R-HSA-211981 )
BioCyc Pathway
MetaCyc:HS08544-MON

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
1 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
AVI-4557 DMQGI73 Anxiety disorder 6B00-6B0Z Phase 2 [1]
------------------------------------------------------------------------------------

References

1 Phosphorodiamidate morpholino antisense oligomers inhibit expression of human cytochrome P450 3A4 and alter selected drug metabolism. Drug Metab Dispos. 2002 Jul;30(7):757-62.